NCI Cancer Research Data Commons: Lessons Learned and Future State.

Erika Kim¹, Tanja Davidsen¹, Brandi N Davis-Dusenbery², Alexander Baumann³, Angela Maggio⁴, Zhaoyi Chen^1,5, Daoud Meerzaman¹, Esmeralda Casas-Silva¹, David Pot⁶, Todd Pihl⁷, John Otridge⁷, Eve Shalley⁸, , Jill S Barnholtz-Sloan^1,9, Anthony R Kerlavage¹

¹Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland.

²Velsera (Seven Bridges), Charlestown, Massachusetts.

³Broad Institute, Cambridge, Massachusetts.

⁴Deloitte Consulting LLP, Arlington, Virginia.

⁵NIH, Bethesda, Maryland.

⁶General Dynamics Information Technology, Falls Church, Virginia.

⁷Frederick National Laboratory for Cancer Research, Frederick, Maryland.

⁸Essex, an Emmes Company, Rockville, Maryland.

⁹Division of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.

PubMed PMC DOI PDF

Abstract

More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations to better understand diseases and ultimately inform the development of better treatments and diagnostic tools. To enable the successful sharing and use of big data, the NCI developed the Cancer Research Data Commons (CRDC), providing access to a large, comprehensi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.